Hopefully these artlicles may help you. I also would look at the package insert and call the company # to inquire.
1: Eur J Contracept Reprod Health Care. 2005;10 Suppl 1:2-6. Links
What women want and what their doctors need--how do women evaluate the quality of contraceptive methods and products introduced by their gynaecologist? A different perspective.van de Weijer P.
Department of Obstetrics & Gynaecology, Gelre Teaching Hospital, PO Box 9014, 7300 DS Apeldoorn, The Netherlands.
Is a doctor really aware of women's expectations and needs when choosing their contraceptive? When faced with making a decision about which contraceptive to chose, women often turn to their doctor for information and guidance. This is particularly the case with oral hormonal contraceptives. Nowadays women often demand more than just a pill that will provide reliable contraception--they expect additional benefits such as good cycle control, improvement in dysmenorrhoea and if possible a beneficial effect on hair and skin. The increased choice of available oral contraceptives places additional pressure on doctors to fully understand the products they are prescribing, in terms of both the physiological and the psychological effects they may have on their patients. Clinical guidelines need to be in place in order to manage any day-to-day problems that may arise. In addition doctors need to re-evaluate their relationship with their patients in order to provide what women really want.
PMID: 16356875 [PubMed - indexed for MEDLINE]
Contraception. 2006 Jan;73(1):30-3. Epub 2005 Nov 16. Links
Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).Barbosa IC, Filho CI, Faggion D Jr, Baracat EC.
Maternidade Climerio de Oliveira, Universidade Federal da Bahia, 40055-150 Salvador, Bahia, Brazil.
[email protected]
OBJECTIVE: A prospective, open-label, noncomparative, multicenter study was carried out in 163 women aged 18-39 (mean 25+/-5 years), who used an ultra-low-dose oral contraceptive pill (OCP) containing gestodene (GTD) 60 mug/ethinylestradiol (EE) 15 mug for 6 months. The objective of the study was to evaluate the acceptability, safety, bleeding patterns and premenstrual symptomatology in these women. METHODS: Patients used the OCP from Days 1-24, followed by a 4-day pill-free interval from Days 25-28 of the menstrual cycle. Physical and gynecological examinations were carried out at baseline and after 3 and 6 months, at which time blood pressure, weight, hemoglobin, hematocrit, SGOT, SGPT and urinalysis were also assessed. The Moos Menstrual Distress Questionnaire (MDQ) was completed on three consecutive days (Days 25-27 of the cycle) at baseline and at the end of the third and sixth cycles. Patients kept a menstrual diary throughout the study. RESULTS: A total of 146 women completed the study. Ten women discontinued because of adverse events and one undesired pregnancy occurred during treatment. No adverse metabolic effects were observed. The adverse event most frequently reported was breakthrough bleeding, which diminished, however, as the time of OC use increased. Cycle length and duration of bleeding decreased significantly with OC use (p<.01 and p<.05, respectively, after 6 months). Intensity of menstrual bleeding tended to decrease with OC use, but this difference was not statistically significant. Systolic and diastolic blood pressure were significantly lower after 6 months of OC use compared to baseline (p<.02). No alterations were recorded in body weight or laboratory evaluations. Statistically significant changes were found both in the total MDQ score and in several of the factors evaluated, and patients showed a statistically significant improvement in well-being with respect to premenstrual complaints and symptoms. CONCLUSION: This OC regimen is safe, well-accepted and well-tolerated, affects menstrual patterns beneficially by reducing both the intensity and duration of bleeding, provides good cycle control and improves premenstrual symptomatology.
PMID: 16371291 [PubMed - indexed for MEDLINE]
: Eur J Contracept Reprod Health Care. 2003 Sep;8(3):162-9. Links
Use of an oral contraceptive containing drospirenone in an extended regimen.Sillem M, Schneidereit R, Heithecker R, Mueck AO.
Gynecological Clinic, Aschaffenburg, Germany.
As well as providing reliable contraception, modern low-dose oral contraceptives may offer some non-contraceptive advantages. Positive effects on problems such as edema with weight increase and breast tenderness, bloating, dysmenorrhea, and an improvement in skin and hair condition have been reported in several studies using an oral contraceptive containing drospirenone. If these disorders are cycle-dependent, use of the contraceptive in an extended regimen may be of additional benefit. The study reported in this paper followed 1433 women, 175 of whom took the drospirenone-containing pill continuously for between 42 and 126 days. Some symptoms of the premenstrual syndrome were influenced very satisfactorily by administration in an extended regimen.
PMID: 14667328 [PubMed - indexed for MEDLINE]
